Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CG Oncology, Inc. Common stock Market Cap
From what 0 stock analysts predict, the share price for CG Oncology, Inc. Common stock (CGON) might increase by 87.37% in the next year. This is based on a 12-month average estimation for CGON. Price targets go from $52 to $86. The majority of stock analysts believe CGON is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedCGON 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect CG Oncology, Inc. Common stock to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CGON. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CGON.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Gregory Renza RBC Capital | Outperform | $66 | Initiates | Sep 23, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Reiterates | Sep 17, 2024 |
| Benjamin Paluch Roth MKM | Buy | $65 | Initiates | Aug 27, 2024 |
| Charlie Yang B of A Securities | Buy | $65 | Initiates | Jun 28, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Reiterates | May 28, 2024 |
| Corinne Johnson Goldman Sachs | Buy | $50 | Upgrade | May 14, 2024 |
| Corinne Johnson Goldman Sachs | Buy | $50 | Upgrade | May 13, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Reiterates | May 10, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Reiterates | May 6, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $75 | Reiterates | May 6, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $75 | Reiterates | May 2, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Reiterates | Apr 4, 2024 |
| Jeffrey Hung Morgan Stanley | Overweight | $55 | Initiates | Feb 20, 2024 |
| Josh Schimmer Cantor Fitzgerald | Overweight | $75 | Initiates | Feb 20, 2024 |
| Corinne Johnson Goldman Sachs | Neutral | $42 | Initiates | Feb 20, 2024 |
| Andres Maldonado HC Wainwright & Co. | Buy | $75 | Initiates | Feb 14, 2024 |
When did it IPO
2024
Staff Count
61
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Arthur Kuan
Market Cap
$2.44B
In 2023, CGON generated $204,000 in revenue, which was a increase of 6.81% from the previous year. This can be seen as a signal that CGON's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 30 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CG Oncology (NASDAQ: CGON) will have CEO Arthur Kuan participate in a fireside chat on September 6, 2024, at 10:45 am ET in New York, discussing its bladder cancer therapeutic developments.
Why It Matters - CG Oncology's CEO participation in the fireside chat may signal potential insights into the company’s development progress and market strategy, influencing investor sentiment and stock performance.
Mon, 26 Aug 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - CG Oncology's cretostimogene achieved a 75.2% complete response rate in a phase 3 study for bladder cancer, targeting BCG-unresponsive NMIBC patients with significant market potential.
Why It Matters - Cretostimogene's 75.2% success rate in phase 3 trials highlights its potential, signaling strong market opportunity and growth for CG Oncology, which can attract investor interest.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CG Oncology reported positive results from the CORE-001 study of Cretostimogene Grenadenorepvec, achieving a 54% complete response rate in BCG-unresponsive NMIBC. The BOND-003 study showed a 75.2% response rate.
Why It Matters - Positive study results for Cretostimogene Grenadenorepvec enhance CG Oncology's potential in bladder cancer treatment, boosting confidence in its market position and future revenue prospects.
Tue, 09 Jul 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - CG Oncology's cretostimogene demonstrates promising efficacy for high-risk NMIBC patients unresponsive to BCG. The potential market exceeds 60,000, but competition from Johnson & Johnson is expected.
Why It Matters - CG Oncology's cretostimogene could capture a substantial market share in NMIBC, appealing to high-risk patients. However, competition from major players like Johnson & Johnson may impact its success.
Thu, 06 Jun 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CG Oncology has announced the publication of final results from the CORE-001 study in Nature Medicine, evaluating Cretostimogene Grenadenorepvec with Pembrolizumab.
Why It Matters - The publication of final results from the CORE-001 study could indicate the potential efficacy of CG Oncology's treatment, influencing stock performance and investor sentiment in biotech.
Fri, 24 May 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CG Oncology (NASDAQ: CGON) announced final results from its Phase 2 CORE-001 trial of cretostimogene combined with pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer.
Why It Matters - Successful Phase 2 trial results for CG Oncology’s cretostimogene could indicate strong market potential, impacting stock performance and attracting investor interest in the biopharmaceutical sector.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
